Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by Trippedstockson Feb 13, 2021 10:32pm
140 Views
Post# 32563655

RE:Remember what Dr.John Fahy said:

RE:Remember what Dr.John Fahy said:
chrisxd5 - if you believe dr. Fahy says it works, would he just watch patients in his hospital go untreated or cared for with inferior treatments? Or would he get them the drug he believes in? The only way for a non-clinical trial hospital to use Bucillamine is to apply under the IND EAP... So would he not have known about the EAP when he signed on? And most likely sooner as MF and him would have been talking the day after his thiol research was released. How many patients are needed to publish top line EAP results? Rlftf was 40 wasn't it? (I don't follow rlftf)

I truly expect EAP results sooner than ph 3.

let's enjoy the weekend now :)
<< Previous
Bullboard Posts
Next >>